Urotensin-II is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig

Life Sciences

Volumn 78, Issue 23, 2006, Pages 2763-2766

  Lacza, Zsombor ^a,b   W Busija, David ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Cerebral circulation; Newborn pig; Nitric oxide; Urotensin II

Indexed keywords

N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; BRAIN CIRCULATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MALE; MICROSCOPY; NEWBORN; NONHUMAN; PIA ARTERY; SWINE; VASOCONSTRICTION; VASODILATATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANIMALS, NEWBORN; CEREBRAL ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; FEMALE; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; SWINE; UROTENSINS; VASODILATOR AGENTS;

ANIMALIA; SUS SCROFA;

EID: 33646030617     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.11.002     Document Type: Article

References (39)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., Louden C.S., Foley J.J., Sauermelch C.F., Coatney R.W., Ao Z., Disa J., Holmes S.D., Stadel J.M., Martin J.D., Liu W.S., Glover G.I., Wilson S., McNulty D.E., Ellis C.E., Elshourbagy N.A., Shabon U., Trill J.J., Hay D.W., Douglas S.A., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. British Journal of Pharmacology 135 (2002) 25-27
3. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. British Journal of Pharmacology 130 (2000) 1865-1870
4. Camarda V., Rizzi A., Calo G., Gendron G., Perron S.I., Kostenis E., Zamboni P., Mascoli F., and Regoli D. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn-Schmiedeberg's Archives of Pharmacology 365 (2002) 141-149
5. Chartrel N., Leprince J., Dujardin C., Chatenet D., Tollemer H., Baroncini M., Balment R.J., Beauvillain J.C., and Vaudry H. Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. Journal of Neurochemistry 91 (2004) 110-118
6. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. Plasma concentration of urotensin II is raised in hypertension. Journal of Hypertension 22 (2004) 1341-1344
7. Domoki F., Perciaccante J.V., Shimizu K., Puskar M., Busija D.W., and Bari F. N-methyl-d-aspartate-induced vasodilation is mediated by endothelium-independent nitric oxide release in piglets. American Journal of Physiology Heart and Circulatory Physiology 282 (2002) H1404-H1409
8. Douglas S.A., Ashton D.J., Sauermelch C.F., Coatney R.W., Ohlstein D.H., Ruffolo M.R., Ohlstein E.H., Aiyar N.V., and Willette R.N. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. Journal of Cardiovascular Pharmacology 36 (2000) S163-S166
9. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., Ohlstein E.H., and Willette R.N. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. British Journal of Pharmacology 131 (2000) 1262-1274
10. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
11. Gardiner S.M., March J.E., Kemp P.A., Davenport A.P., and Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. British Journal of Pharmacology 132 (2001) 1625-1629
12. Gilbert R.E., Douglas S.A., and Krum H. Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease. Current Opinion in Investigational Drugs 5 (2004) 276-282
13. Hillier C., Berry C., Petrie M.C., O'Dwyer P.J., Hamilton C., Brown A., and McMurray J. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103 (2001) 1378-1381
14. Itoh H., McMaster D., and Lederis K. Functional receptors for fish neuropeptide urotensin II in major rat arteries. European Journal of Pharmacology 149 (1988) 61-66
15. Katano Y., Ishihata A., Aita T., Ogaki T., and Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. European Journal of Pharmacology 402 (2000) R5-R7
16. Lacza Z., Erdos B., Gorlach C., Wahl M., Sandor P., and Benyo Z. The cerebrocortical microcirculatory effect of nitric oxide synthase blockade is dependent upon baseline red blood cell flow in the rat. Neuroscience Letters 291 (2000) 65-68
17. Lacza Z., Puskar M., Kis B., Perciaccante J.V., Miller A.W., and Busija D.W. Hydrogen peroxide acts as an EDHF in the piglet pial vasculature in response to bradykinin. American Journal of Physiology Heart and Circulatory Physiology 283 (2002) H406-H411
18. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., and Gilbert R.E. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. American Journal of Kidney Diseases 44 (2004) 826-831
19. Lim M., Honisett S., Sparkes C.D., Komesaroff P., Kompa A., and Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 109 (2004) 1212-1214
20. Lin L., Ding W.H., Jiang W., Zhang Y.G., Qi Y.F., Yuan W.J., and Tang C.S. Urotensin-II activates l-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 25 (2004) 1977-1984
21. Lin Y., Tsuchihashi T., Matsumura K., Fukuhara M., Ohya Y., Fujii K., and Iida M. Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertension Research 26 (2003) 839-845
22. Liu Q., Pong S.S., Zeng Z., Zhang Q., Howard A.D., Williams D.L.J., Davidoff M., Wang R., Austin C.P., McDonald T.P., Bai C., George S.R., Evans J.F., and Caskey C.T. Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochemical and Biophysical Research Communications 266 (1999) 174-178
23. Lu Y., Zou C.J., Huang D.W., and Tang C.S. Cardiovascular effects of urotensin II in different brain areas. Peptides 23 (2002) 1631-1635
24. Maguire J.J., Kuc R.E., and Davenport A.P. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. British Journal of Pharmacology 131 (2000) 441-446
25. Maguire J.J., Kuc R.E., Wiley K.E., Kleinz M.J., and Davenport A.P. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25 (2004) 1767-1774
26. Mimassi N., Shahbazi F., Jensen J., Mabin D., Conlon J.M., and Le Mevel J.C. Cardiovascular actions of centrally and peripherally administered trout urotensin-I in the trout. American Journal of Physiology Regulative, Integrative and Comparatory Physiology 279 (2000) R484-R491
27. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
28. Pearson D., Shively J.E., Clark B.R., Geschwind I.I., Barkley M., Nishioka R.S., and Bern H.A. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proceedings of the National Academy of Sciences of the United States of America 77 (1980) 5021-5024
29. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
30. Russell F.D. Emerging roles of urotensin-II in cardiovascular disease. Pharmacology and Therapeutics 103 (2004) 223-243
31. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., and Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. American Journal of Physiology Heart and Circulatory Physiology 285 (2003) H1576-H1581
32. Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., Berry C., Kirk A., Richardson M., and MacLean M.R. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. American Journal of Physiology Heart and Circulatory Physiology 280 (2001) H925-H928
33. Thompson J.P., Watt P., Sanghavi S., Strupish J.W., and Lambert D.G. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesthesia and Analgesia 97 (2003) 1501-1503
34. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., Kimura Y., Sasano H., and Murakami O. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
35. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clinical Science (Lond) 104 (2003) 1-5
36. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., Kikuya M., Ohkubo T., Hashimoto J., and Imai Y. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptide 25 (2004) 1809-1814
37. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., Kelly D.J., Gilbert R.E., and Krum H. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circulation Research 93 (2003) 246-253
38. Watson A.M., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
39. Zhang A.Y., Chen Y.F., Zhang D.X., Yi F.X., Qi J., Andrade-Gordon P., de Garavilla L., Li P.L., and Zou A.P. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. American Journal of Physiology Renal Physiology 285 (2003) F792-F798